---
title: "Alembic Pharmaceuticals Ltd (APLLTD) — Share Price, Financials & Analysis"
symbol: "APLLTD"
company: "Alembic Pharmaceuticals Ltd"
canonical: "https://tapetide.com/stocks/APLLTD"
isin: "INE901L01018"
nse_symbol: "APLLTD"
bse_code: "533573"
sector: "Healthcare"
industry: "Pharmaceuticals"
market_cap_cr: 15754.53
generated_at: "2026-09-13T18:47:32.122Z"
---

# Alembic Pharmaceuticals Ltd (APLLTD)

Canonical page: https://tapetide.com/stocks/APLLTD

## Company

- **NSE Symbol:** APLLTD
- **BSE Code:** 533573
- **ISIN:** INE901L01018
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2011-09-20
- **CEO:** Mr. Chirayu Ramanbhai Amin
- **Employees:** 16571
- **Face Value:** ₹2
- **F&O Eligible:** No
- **Website:** alembic-india.com

## About

Alembic Pharmaceuticals is in the business of development, manufacturing, and marketing of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients.
The company has 3 R&D and 5 manufacturing facilities.

## Latest Price

- **Price:** ₹810.95
- **Change:** -5.45 (-0.67%)
- **Open:** ₹806
- **Day High:** ₹822
- **Day Low:** ₹799.2
- **Previous Close:** ₹816.4
- **Volume:** 118504
- **As Of:** 2026-09-11T10:26:57+00:00

## Key Fundamentals

Observed at 2026-09-11T04:39:25.935706Z.

- **Market Cap:** ₹15754.53 Cr
- **Classification:** Smallcap
- **P/E (reported):** 23.3
- **P/E (TTM):** 22.99
- **EPS (TTM):** ₹35.27
- **EPS (reported):** ₹32.05
- **Book Value:** ₹288.7
- **Price to Book:** 2.83
- **Dividend Yield:** 1.47%
- **ROE:** 11.83%
- **ROCE:** 12.77%
- **Debt to Equity:** 0.25
- **Revenue (yearly):** ₹7399.3 Cr
- **Net Income:** ₹670.8 Cr
- **EBITDA:** ₹1172.9 Cr
- **52-Week High:** ₹998
- **52-Week Low:** ₹635.8
- **RSI (14):** 49.63

## Tapetide Score

- **Score:** 52 / 100
- **Score date:** 2026-09-04
- **Archetype:** Cheap but Weak
- **What it means:** A low multiple sitting on weak financials. Worth establishing what the market is discounting before treating the low valuation as an opportunity — weak fundamentals often justify it.
- **Pillar profile:** Quality: Weak · Valuation: Cheap · Momentum: Falling
- **Percentile:** 56.6 (of 4473 scored stocks)
- **Confidence:** 100%
- **Data coverage:** 100%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 35.26 | 9% |
| growth | 43.71 | 9% |
| momentum | 40.96 | 12% |
| ownership | 55.82 | 24% |
| quality | 33.34 | 22% |
| valuation | 80.52 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Company has been maintaining a healthy dividend payout of 35.7%

### Weaknesses

- Stock is trading at 2.81 times its book value
- The company has delivered a poor sales growth of 6.37% over past five years.
- Tax rate seems low
- Company has a low return on equity of 12.7% over last 3 years.
- Company might be capitalizing the interest cost

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | 789.87% | -2.55% | 41.71% |
| ebitda margin growth | 51.09% | 1.28% | 3.12% | -8.17% |
| net income growth | -14.44% | 15.26% | 28% | -9% |
| revenue growth | 15.52% | 10.2% | 9% | 6% |
| roce | 76.7% | -12.89% | -7.4% | 12.4% |
| roe | -14.47% | 5.44% | 11.94% | 18.89% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 1595 | 1631 | 1517 | 1562 | 1648 | 1693 | 1770 | 1711 | 1910 | 1876 | 1848 | 2150 |
| Expenses | 1387 | 1364 | 1257 | 1325 | 1409 | 1433 | 1498 | 1430 | 1594 | 1585 | 1620 | 1818 |
| Operating Profit | 208 | 266 | 260 | 237 | 239 | 260 | 271 | 281 | 316 | 292 | 228 | 332 |
| OPM % | 13 | 16 | 17 | 15 | 15 | 15 | 15 | 16 | 17 | 16 | 12 | 15 |
| Other Income | 10 | 3 | 4 | 2 | 30 | 10 | 14 | 6 | 8 | -27 | 2 | 15 |
| Interest | 16 | 15 | 11 | 13 | 19 | 22 | 25 | 24 | 24 | 23 | 23 | 28 |
| Depreciation | 68 | 69 | 69 | 69 | 71 | 70 | 69 | 74 | 76 | 80 | 89 | 98 |
| Profit before tax | 135 | 185 | 183 | 157 | 180 | 178 | 192 | 190 | 224 | 162 | 119 | 222 |
| Tax % | -1 | 2 | 3 | 14 | 15 | 23 | 18 | 19 | 18 | 18 | -70 | 22 |
| Net Profit | 137 | 180 | 178 | 135 | 153 | 138 | 157 | 154 | 184 | 132 | 202 | 172 |
| EPS in Rs | 6.95 | 9.18 | 9.07 | 6.85 | 7.8 | 7.04 | 7.98 | 7.85 | 9.4 | 6.76 | 10.31 | 8.8 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 3131 | 3935 | 4606 | 5393 | 5306 | 5653 | 6229 | 6672 | 7345 | 7784 |
| Expenses | 2488 | 3061 | 3383 | 3913 | 4432 | 4970 | 5296 | 5664 | 6224 | 6617 |
| Operating Profit | 643 | 874 | 1223 | 1480 | 874 | 682 | 932 | 1008 | 1121 | 1167 |
| OPM % | 21 | 22 | 27 | 27 | 16 | 12 | 15 | 15 | 15 | 15 |
| Other Income | 7 | 9 | -39 | 87 | 56 | -2 | 28 | 56 | -14 | -1 |
| Interest | 3 | 18 | 27 | 16 | 18 | 50 | 56 | 79 | 94 | 98 |
| Depreciation | 105 | 115 | 157 | 183 | 287 | 275 | 273 | 279 | 319 | 342 |
| Profit before tax | 541 | 749 | 1000 | 1368 | 625 | 355 | 632 | 707 | 694 | 726 |
| Tax % | 22 | 21 | 20 | 19 | 17 | 4 | 3 | 18 | 3 | — |
| Net Profit | 413 | 583 | 801 | 1146 | 521 | 342 | 616 | 582 | 671 | 690 |
| EPS in Rs | 21.89 | 31 | 43.97 | 58.33 | 26.5 | 17.4 | 31.33 | 29.68 | 34.33 | 35.27 |
| Dividend Payout % | 18 | 18 | 23 | 24 | 38 | 46 | 35 | 37 | 35 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 38 | 38 | 38 | 38 | 39 | 39 | 39 | 39 | 39 | 39 |
| Reserves | 1865 | 2182 | 2681 | 3182 | 5028 | 5198 | 4331 | 4779 | 5152 | 5636 |
| Borrowings | 89 | 708 | 1128 | 1747 | 584 | 717 | 722 | 513 | 1258 | 1430 |
| Other Liabilities | 698 | 1013 | 931 | 1022 | 1058 | 1167 | 1090 | 1114 | 1325 | 1658 |
| Total Liabilities | 2689 | 3941 | 4778 | 5989 | 6709 | 7122 | 6183 | 6446 | 7773 | 8763 |
| Fixed Assets | 799 | 993 | 1158 | 1552 | 1788 | 1798 | 2398 | 2547 | 2524 | 3081 |
| CWIP | 396 | 1010 | 1551 | 1846 | 2183 | 2304 | 601 | 524 | 837 | 683 |
| Investments | 50 | 42 | 49 | 18 | 236 | 118 | 96 | 93 | 127 | 141 |
| Other Assets | 1444 | 1896 | 2019 | 2573 | 2502 | 2902 | 3087 | 3281 | 4285 | 4858 |
| Total Assets | 2689 | 3941 | 4778 | 5989 | 6709 | 7122 | 6183 | 6446 | 7773 | 8763 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 329 | 312 | 812 | 449 | 1463 | 552 | 724 | 803 | 88 | 783 |
| Cash from Investing Activity | -486 | -884 | -756 | -731 | -840 | -372 | -448 | -321 | -568 | -506 |
| Cash from Financing Activity | -129 | 503 | 59 | 155 | -597 | -217 | -262 | -438 | 444 | -164 |
| Net Cash Flow | -286 | -69 | 115 | -127 | 26 | -37 | 14 | 45 | -37 | 113 |
| Free Cash Flow | 348 | -495 | 49 | -285 | 804 | 128 | 282 | 487 | -466 | 290 |
| CFO/OP | 73 | 70 | 112 | 56 | 115 | 77 | 115 | 88 | 16 | 79 |

### Ratios

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 40 | 61 | 45 | 69 | 24 | 56 | 68 | 60 | 77 | 73 |
| Inventory Days | 269 | 302 | 356 | 417 | 431 | 406 | 315 | 350 | 466 | 462 |
| Days Payable | 213 | 313 | 237 | 220 | 194 | 178 | 145 | 157 | 179 | 154 |
| Cash Conversion Cycle | 96 | 51 | 164 | 266 | 261 | 283 | 237 | 253 | 363 | 381 |
| Working Capital Days | 61 | 69 | 24 | 50 | 73 | 74 | 77 | 88 | 87 | 87 |
| ROCE % | 29 | 22 | 23 | 24 | 26 | 11 | 7 | 13 | 13 | 13 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 69.61% | 69.61% | 69.61% | 69.61% | 69.61% | 69.61% | 69.67% | 69.67% | 69.74% | 69.74% | 69.74% | 69.87% |
| FIIs | 4.51% | 4.52% | 4.46% | 4.32% | 3.94% | 4.17% | 3.94% | 3.96% | 4.05% | 4.24% | 4.25% | 4.18% |
| DIIs | 13.93% | 14.5% | 15.38% | 15.47% | 16.05% | 16.06% | 16.43% | 16.46% | 16.3% | 16.17% | 16.18% | 15.94% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 8.24% | 8% | 7.41% | 7.48% | 7.36% | 7.26% | 7.07% | 7.01% | 6.93% | 6.87% | 6.86% | 6.97% |
| Others | 3.71% | 3.37% | 3.14% | 3.13% | 3.04% | 2.9% | 2.88% | 2.89% | 2.99% | 2.98% | 2.96% | 3.03% |
| No. of Shareholders | 89552 | 85212 | 76567 | 74829 | 91429 | 93944 | 91336 | 89013 | 89969 | 87000 | 86432 | 86796 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Sell
- **Buy / Neutral / Sell:** 4 / 7 / 8

### Moving Averages — summary: **Strong Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 817.03 | Sell |
| EMA (10) | 814.52 | Sell |
| SMA (20) | 817.65 | Sell |
| EMA (20) | 816.78 | Sell |
| SMA (50) | 821.05 | Sell |
| EMA (50) | 811.66 | Sell |
| SMA (100) | 791.7 | Buy |
| EMA (100) | 800.77 | Buy |
| SMA (200) | 786.77 | Buy |
| EMA (200) | 807.71 | Buy |

### Oscillators — summary: **Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 47.51 | Neutral |
| MACD (12,26,9) | -1.74 | Sell |
| Stochastic (14,3,3) | 33.61 | Neutral |
| ADX (14) | 15.14 | Neutral |
| Williams %R (14) | -72.36 | Neutral |
| ATR (14) | 23.3 | Neutral |
| ROC (12) | -1.68 | Sell |
| Stoch RSI (14) | 28.52 | Neutral |
| UO (7,14,28) | 41.73 | Neutral |

## Analyst Ratings

| Recommendation | Analysts | Share |
| --- | --- | --- |
| Buy | 5 | 55.56% |
| Hold | 4 | 44.44% |
| Sell | 0 | 0% |

Based on 9 analyst ratings, observed at 2026-09-11T04:39:27.624483+00:00.

## Filings & Documents

### Other Documents

| Date | Document |
| --- | --- |
| 9 Mar - Incorporated Alembic Pharmaceuticals (Thailand) Co., Ltd on Mar 9, 2026; share capital Baht 3,000,000; Alembic holds 99.99%. | [Intimation Under Regulation 30 Of SEBI (LODR) Regulations, 2015 - Incorporation Of Subsidiary 9 Mar - Incorporated Alembic Pharmaceuticals (Thailand) Co., Ltd on Mar 9, 2026; share capital Baht 3,000,000; Alembic holds 99.99%.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/4a169955-8f8f-4473-a20b-99bd8fdea26c.pdf) |
| 8h - Pranav Amin re-appointed Managing Director for five years effective 1 April 2026 (AGM approved 5 Aug 2025). | [Announcement under Regulation 30 (LODR)-Change in Directorate 8h - Pranav Amin re-appointed Managing Director for five years effective 1 April 2026 (AGM approved 5 Aug 2025).](https://www.bseindia.com/xml-data/corpfiling/AttachLive/c09f44aa-d9ee-4772-aac2-b3258ac25846.pdf) |
| 8h - Alembic Pharmaceuticals incorporated Alembic Lifesciences Philippines Inc. in Philippines for pharma business opportunities. | [Intimation Under Regulation 30 Of SEBI LODR Regulations, 2015 - Incorporation Of Subsidiary Company 8h - Alembic Pharmaceuticals incorporated Alembic Lifesciences Philippines Inc. in Philippines for pharma business opportunities.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/93d1258a-65e4-4b4d-8b5f-25df4d19777c.pdf) |
| 8 Apr - Certificate under Regulation 74(5) of the SEBI (DP) Regulations, 2018 for the quarter ended 31st March, 2026. | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 8 Apr - Certificate under Regulation 74(5) of the SEBI (DP) Regulations, 2018 for the quarter ended 31st March, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/38862b49-38e9-48cf-aa50-6ce1a5e1bee3.pdf) |
| 7 Apr - Alembic gets USFDA final approval for Dapagliflozin 5 mg and 10 mg tablets, eligible for 180-day exclusivity. | [Announcement under Regulation 30 (LODR)-Press Release / Media Release 7 Apr - Alembic gets USFDA final approval for Dapagliflozin 5 mg and 10 mg tablets, eligible for 180-day exclusivity.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/b17bd3f0-d737-4a9d-bdce-a5ee5069a279.pdf) |
| 6h - Nilesh Wadhwa, Head—Formulation Business Development, resigned; relieved effective 31 March 2026 (after business hours). | [Announcement under Regulation 30 (LODR)-Change in Management 6h - Nilesh Wadhwa, Head—Formulation Business Development, resigned; relieved effective 31 March 2026 (after business hours).](https://www.bseindia.com/xml-data/corpfiling/AttachLive/b654c0d5-c9a6-4be6-bd62-bf2768048f4d.pdf) |
| 6h - Members approved appointment of Rajkumar Baheti and professional fees on March 31, 2026 via postal ballot. | [Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot 6h - Members approved appointment of Rajkumar Baheti and professional fees on March 31, 2026 via postal ballot.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/7deba86d-4eef-4dec-902f-57fce2a46bc6.pdf) |
| 6h - Appointed Rajkumar Baheti as Non‑Executive Non‑Independent Director; approved his professional fees; passed March 31, 2026. | [Shareholder Meeting / Postal Ballot-Scrutinizer"s Report 6h - Appointed Rajkumar Baheti as Non‑Executive Non‑Independent Director; approved his professional fees; passed March 31, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/8f4dd453-cdff-4297-acd3-9b3ebf4d3228.pdf) |
| 6 Mar - One-on-one meeting with Bajaj Finserv AMC on 11 March 2026 in Vadodara. | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 6 Mar - One-on-one meeting with Bajaj Finserv AMC on 11 March 2026 in Vadodara.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/249a6874-3f16-46e1-9bc0-75a80cf919cd.pdf) |
| 6 Mar - 6 Mar 2026: Alembic reports first US prescription sale of Pivya (pivmecillinam) after commercial launch. | [Announcement under Regulation 30 (LODR)-Press Release / Media Release 6 Mar - 6 Mar 2026: Alembic reports first US prescription sale of Pivya (pivmecillinam) after commercial launch.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/6510b220-3b2c-4a38-b775-df07ed430f44.pdf) |

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-09-07 | [Intimation Under Regulation 30 Of SEBI LODR Regulations 2015 - Incorporation Of A Wholly Owned Subsidiary Company](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f9b6c28f-f7cf-4aa2-8349-3a911bbcb682.pdf) |
| 2026-08-27 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ddba2457-9573-4e0f-9635-4afc762f89cf.pdf) |
| 2026-08-27 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e18fda9e-73b6-44f7-8f54-0b885f26b1ae.pdf) |
| 2026-08-25 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=14a850e4-d357-4006-ac8d-bc7e6579b043.pdf) |
| 2026-08-20 | [Appointment of Company Secretary and Compliance Officer](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e367811f-3d8a-4074-a5a3-601c06ccf3ed.pdf) |
| 2026-08-11 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cfc87728-6564-4bfe-8034-bfef3fb90201.pdf) |
| 2026-08-10 | [Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=47145270-a2ac-4e2a-82e9-c40b78022f77.pdf) |
| 2026-08-06 | [Shareholder Meeting / Postal Ballot-Scrutinizers Report](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f91f0de0-eaf2-4ddf-8070-75562d4cf18e.pdf) |
| 2026-08-05 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ad39a252-91a5-43b0-8cb7-ac8ed69d7769.pdf) |
| 2026-08-05 | [Shareholder Meeting / Postal Ballot-Outcome of AGM](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bb00ddde-c4ea-4f79-8d42-bc9beee755aa.pdf) |

### Earnings Call Transcripts

| Date | Document |
| --- | --- |
| 2026-08-10 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b8f27d1b-f644-4885-a463-793dbbfce7ca.pdf) |
| 2026-05-21 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1e5987cb-3bd7-4832-852e-ec765d86c045.pdf) |
| 2026-02-11 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7eca3970-89d2-42e5-ba67-8ab7bc7e1dc9.pdf) |
| 2025-11-11 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6924be80-9862-464e-a101-818e32429b4a.pdf) |
| 2025-08-11 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=aba494e6-578f-473d-9265-6714f15dcd32.pdf) |
| 2025-05-12 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0aef0e86-5752-47d8-92db-937dfd500357.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-08-04 | [Unaudited Financial Results For The Quarter Ended June 30 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=54cb1388-fe47-4e0b-ab5a-8aad4401e3da.pdf) |
| 2026-05-15 | [Audited Financial Results For The Quarter And Financial Year Ended 31St March 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d4769a28-ab13-4fb6-b56f-7cde008b26de.pdf) |
| 2026-02-05 | [Unaudited Financial Results For Quarter And Nine Months Ended 31St December 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4e184f18-4280-4bd6-9651-fc572826dbde.pdf) |
| 2025-11-04 | [Unaudited Financial Results For The Quarter And Half Year Ended 30Th September 2025.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=61b69ed5-405a-4863-8aa0-4e2b2b983e92.pdf) |
| 2025-08-05 | [Unaudited Financial Results For The Qtr Ended 30Th June 2025.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cefcecec-aceb-453e-85f8-e1b83fd2b5de.pdf) |
| 2025-05-06 | [Board Meeting Outcome for Please Find Attached Herewith The Outcome Of Board Meeting](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=570a7297-1b32-45b9-83fe-1405171a664f.pdf) |
| 2025-05-06 | [Financial Results For The Quarter And Financial Year Ended 31St March 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=da588a9e-d79f-4c45-aca0-a50e01bd1602.pdf) |
| 2025-02-03 | [Results For The Quarter And Nine Months Ended 31St December 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c8bea75b-3c20-44cf-87d8-ca9409741f82.pdf) |

### Investor Presentations

| Date | Document |
| --- | --- |
| 2026-08-04 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d85cc438-3429-4b83-a89a-b1afb9824454.pdf) |
| 2026-05-15 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7304396a-752a-453f-9789-5d41d3d422c0.pdf) |
| 2026-02-05 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d92917fa-fbdb-465c-bab7-1d2b1baaccf1.pdf) |
| 2026-02-05 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=46c93f24-1700-455c-b9cd-ab997c99dfbc.pdf) |
| 2025-11-04 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7517e5c0-3e56-45fc-acd9-d392c6e0f2a9.pdf) |
| 2025-08-05 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=83d227fb-47b0-46f6-8347-601c06bb1b4c.pdf) |
| 2025-05-06 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fc5456a4-8aaa-4a0b-b1b4-79046750b3f1.pdf) |
| 2025-02-03 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=404caac6-1986-45e2-a318-fb6c9d5e9db2.pdf) |

### Earnings Call Recordings

| Date | Document |
| --- | --- |
| 2026-08-04 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8b198e92-a6f2-4161-9f0a-b5f840433898.pdf) |
| 2026-02-05 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8cc9e401-65c8-4f78-9667-24920ae9e549.pdf) |
| 2025-11-04 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=aa23abbc-df33-4317-ade0-afa39e00919b.pdf) |
| 2025-08-05 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9fbf5cc2-c97c-4231-ae49-d56e6960a0cd.pdf) |
| 2025-05-06 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=80ac3eb5-e214-4a21-919f-33239b2a419c.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Nov 2025 | [Concall - Nov 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/6924be80-9862-464e-a101-818e32429b4a.pdf) |
| Nov 2025 | [Concall - Nov 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/c0f6a3d5-8ebe-45fb-94bb-bec5cda520aa.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/1e5987cb-3bd7-4832-852e-ec765d86c045.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachLive/1e5987cb-3bd7-4832-852e-ec765d86c045.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/7304396a-752a-453f-9789-5d41d3d422c0.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachLive/7304396a-752a-453f-9789-5d41d3d422c0.pdf) |
| May 2025 | [Concall - May 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/0aef0e86-5752-47d8-92db-937dfd500357.pdf) |
| May 2025 | [Concall - May 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/5ae00eb7-b6aa-44af-99ff-26523fed21ca.pdf) |
| Feb 2026 | [Concall - Feb 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/d92917fa-fbdb-465c-bab7-1d2b1baaccf1.pdf) |
| Feb 2026 | [Concall - Feb 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/7eca3970-89d2-42e5-ba67-8ab7bc7e1dc9.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from bse | [Annual Report 2026 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/4d85deb6-8396-413c-b3d8-566a65d417e5.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T18:47:32.122Z.